Dr. Eloise Chapman-Davis, MD

Dr. Chapman-Davis practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Chapman-Davis' NPI, 1689707606, was assigned on March 13, 2007. Dr. Chapman-Davis graduated from Renaissance School of Medicine at Stony Brook University in 2004. Dr. Chapman-Davis' New York license number on file is 281767.

Dr. Chapman-Davis' primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Chapman-Davis' primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. The medical group on file is Weill Cornell Physicians. Dmand AI also links Dr. Chapman-Davis to 2 more clinical labs, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chapman-Davis practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Chapman-Davis' primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Chapman-Davis is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Chapman-Davis' licenses on file in 3 states: New York, Massachusetts and Illinois.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Chapman-Davis treats.

CMS data shows 429 Medicare services from Dr. Chapman-Davis across 6 procedure codes in 2024, for 121 Medicare patients. Medicare paid $35,958 for them.

CMS counts 121 Medicare patients who saw Dr. Chapman-Davis in 2024. The largest group is 75 to 84, with 56 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chapman-Davis' median patient age at 70, with 98% women.

In 2024, Dr. Chapman-Davis wrote 62 Medicare Part D claims for 29 patients. 89% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $1,265 in total drug cost. In 2022, CMS named 53 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Chapman-Davis for performance year 2024, reported through an alternative payment model (APM). Dr. Chapman-Davis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chapman-Davis as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 82 papers to Dr. Chapman-Davis, published from 2010 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Ovarian Neoplasms, Genital Neoplasms, Female and COVID-19. Dr. Chapman-Davis has published most often in Gynecol Oncol. Dr. Chapman-Davis' most frequent co-authors are Melissa Kristen Frey, MD, Kevin M. Holcomb, MD and Evelyn Cantillo, MD.

Dmand AI links Dr. Chapman-Davis to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Behavior, Breast Neoplasms and Ovarian Neoplasms. Weill Medical College of Cornell University sponsors the most, 2.

CMS Open Payments shows 14 general payments to Dr. Chapman-Davis from 6 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 52% of the total. Medical Device Business Services, Inc. paid the most, $849.

Dr. Chapman-Davis serves on Tufts University School of Medicine Admission Committee.

Dr. Chapman-Davis graduated from Renaissance School of Medicine at Stony Brook University in 2004. Dr. Chapman-Davis is a member of ASCO and Society of Gynecologic Oncologists.

Dr. Chapman-Davis is in network with 15 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.